Dapeng Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Dapeng Li has a total of 127 co-authors. Here are the top co-authors by number of shared publications:
He Zhang
Department of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu, 610041, China
7 shared publications- Jin Qi
Research Center for Traceability and Standardization of TCMs, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing 211198, China
6 shared publications Zi Yang
Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug, West China School of Pharmacy, Sichuan University, Chengdu, 610041, China
6 shared publications- Bo-Yang Yu
Jiangsu Key Laboratory of TCM Evaluation and Translational Research, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing, China
5 shared publications Qian Yang
Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug, West China School of Pharmacy, Sichuan University, Chengdu, 610041, China
5 shared publicationsYanruyu Feng
Key Laboratory of Drug Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu 610041, China
5 shared publications
Latest Publications
- Open Access
- 1 July 2026
- Published by KEAI Publishing in Glycoscience & Therapy
- Vol. 2 (4)
N-Glycosylation in Organ Fibrosis from Mechanistic Regulation to Biomarker and Therapeutic Translation
- 1 July 2026
- Published by KEAI Publishing in Glycoscience & Therapy
- Vol. 2 (4)
Open AccessN-Glycosylation in Organ Fibrosis from Mechanistic Regulation to Biomarker and Therapeutic Translation
- 1 March 2026
- Published by Elsevier in Analytica Chimica Acta
- Vol. 1400, 345316
Dual-layer N-glycoproteomics enhances resolution of serum glycosylation signatures in type 2 diabetes mellitus complicated with coronary heart disease
- 1 March 2026
- Published by Elsevier in Analytica Chimica Acta
- Vol. 1400, 345316
Dual-layer N-glycoproteomics enhances resolution of serum glycosylation signatures in type 2 diabetes mellitus complicated with coronary heart disease
- 25 February 2026
- Published by American Chemical Society (ACS) in Journal of Proteome Research
- Vol. 25 (3) , 1213-1225
Proteomics Strategies for Mass Spectrometry Analysis of Host Cell Proteins in Monoclonal Antibody Bioprocessing
Host cell proteins (HCPs) are critical process-related impurities in monoclonal antibody (mAb) production that can compromise product safety, efficacy, and stability. Traditional enzyme-linked immunosorbent assays (ELISA) provide total HCP quantification but lack the specificity to detect individual high-risk species. While mass spectrometry (MS) has emerged as a powerful orthogonal approach, offering molecular-level resolution, high sensitivity, and the ability to identify and quantify low-abundance, potentially immunogenic HCPs. This review provides a strategy-oriented and practice-driven analysis of MS-based HCP analytics, emphasizing how recent methodological advances address real-world challenges in bioprocess development and regulatory compliance. We critically examine optimized sample preparation workflows, including buffer and matrix mitigation, native and denaturing digestion, antibody depletion, and HCP enrichment, alongside multidimensional chromatographic separations and advanced acquisition strategies spanning DDA, DIA, and targeted MS. Particular attention is given to emerging hybrid and integrated workflows, such as DDA-PRM-dMRM acquisition schemes, that bridge discovery and routine quality control. Beyond these, our review places MS-based HCP analysis in evolving global regulatory expectations, providing a comparative and practical interpretation of guidance from the USP, EP, JP, BP, and ChP, with emphasis on validation, standardization, and interlaboratory reproducibility. By integrating technical advances with regulatory frameworks and case-based evidence, our review highlights how MS is transitioning from a supportive characterization tool to a core component of risk-based and multiattribute HCP control strategies in modern biopharmaceutical development.
- 25 February 2026
- Published by American Chemical Society (ACS) in Journal of Proteome Research
- Vol. 25 (3) , 1213-1225
Proteomics Strategies for Mass Spectrometry Analysis of Host Cell Proteins in Monoclonal Antibody Bioprocessing
Host cell proteins (HCPs) are critical process-related impurities in monoclonal antibody (mAb) production that can compromise product safety, efficacy, and stability. Traditional enzyme-linked immunosorbent assays (ELISA) provide total HCP quantification but lack the specificity to detect individual high-risk species. While mass spectrometry (MS) has emerged as a powerful orthogonal approach, offering molecular-level resolution, high sensitivity, and the ability to identify and quantify low-abundance, potentially immunogenic HCPs. This review provides a strategy-oriented and practice-driven analysis of MS-based HCP analytics, emphasizing how recent methodological advances address real-world challenges in bioprocess development and regulatory compliance. We critically examine optimized sample preparation workflows, including buffer and matrix mitigation, native and denaturing digestion, antibody depletion, and HCP enrichment, alongside multidimensional chromatographic separations and advanced acquisition strategies spanning DDA, DIA, and targeted MS. Particular attention is given to emerging hybrid and integrated workflows, such as DDA-PRM-dMRM acquisition schemes, that bridge discovery and routine quality control. Beyond these, our review places MS-based HCP analysis in evolving global regulatory expectations, providing a comparative and practical interpretation of guidance from the USP, EP, JP, BP, and ChP, with emphasis on validation, standardization, and interlaboratory reproducibility. By integrating technical advances with regulatory frameworks and case-based evidence, our review highlights how MS is transitioning from a supportive characterization tool to a core component of risk-based and multiattribute HCP control strategies in modern biopharmaceutical development.
- 7 February 2026
- Published by Springer Nature in Microchimica Acta
- Vol. 193 (3) , 144
Machine learning-assisted multi-aptamer encoding enables pattern-level discrimination of HbA1c in complex biological matrices
- 7 February 2026
- Published by Springer Nature in Microchimica Acta
- Vol. 193 (3) , 144
Machine learning-assisted multi-aptamer encoding enables pattern-level discrimination of HbA1c in complex biological matrices
- 15 August 2025
- Published by Elsevier in Phytomedicine
- Vol. 147, 157172
Celastrol ameliorates metabolic dysfunction associated steatohepatitis by regulating the CYP7B1-mediated alternative bile acid synthetic pathway
- 15 August 2025
- Published by Elsevier in Phytomedicine
- Vol. 147, 157172
Celastrol ameliorates metabolic dysfunction associated steatohepatitis by regulating the CYP7B1-mediated alternative bile acid synthetic pathway
- Open Access
- 2 June 2025
- Published by Elsevier in Journal of Pharmaceutical Analysis
- Vol. 16 (2)
CRISPR screening redefines therapeutic target identification and drug discovery with precision and scalability
- 2 June 2025
- Published by Elsevier in Journal of Pharmaceutical Analysis
- Vol. 16 (2)
Open AccessCRISPR screening redefines therapeutic target identification and drug discovery with precision and scalability
- 24 May 2025
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 350, 120031
Santali Albi Lignum: From traditional efficacies to pharmacological properties and modern therapeutic applications
- 24 May 2025
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 350, 120031
Santali Albi Lignum: From traditional efficacies to pharmacological properties and modern therapeutic applications
- 24 May 2025
- Published by Springer Nature in Analytical and Bioanalytical Chemistry
- Vol. 417 (17) , 3893-3908
Advanced N-glycoproteomics and proteomics approach revealed sexually dimorphic molecular signatures in primary mouse hepatocyte
Sexual dimorphism plays a critical role in disease pathophysiology, but the subtlety and complexity of these differences, along with a lack of precise comparative methods, hinder the advancement of precision medicine and drug development. This limitation is particularly evident in metabolic dysfunction–associated steatotic liver disease (MASLD), where sex-specific molecular mechanisms remain insufficiently understood. To address this gap, we employed an advanced integrative N-glycoproteomics and proteomics approach to systematically analyze sex-biased molecular signatures in primary mouse hepatocytes (PMHs) under healthy and MASLD conditions. Our analysis identified 280 sex-biased proteins and 39 sex-biased N-glycosites, and KEGG enrichment revealed that female-biased molecules were primarily involved in lipid metabolism, while male-biased molecules were associated with inflammation and cytoskeletal remodeling. A combined dataset of 302 sex-biased molecules was further analyzed using protein–protein interaction (PPI) analysis and Rc value calculations, resulting in the identification of 21 hub proteins and 2 hub N-glycosites as MASLD-associated sex-biased signatures. Notably, MASLD amplified proteomic sex differences while attenuating them in N-glycosylation. Western blot validation of key signatures, including female-biased MVK and male-biased LGALS3, highlighted distinct molecular adaptations between the sexes in MASLD progression. Our study introduced an advanced analytical framework for high-resolution comparative molecular profiling by integrating N-glycoproteomics with proteomics, providing valuable insights into sex-biased molecular signatures, enhancing preclinical model development, and advancing sex-specific therapeutic strategies in MASLD research and broader biological systems. Graphical Abstract
- 24 May 2025
- Published by Springer Nature in Analytical and Bioanalytical Chemistry
- Vol. 417 (17) , 3893-3908
Advanced N-glycoproteomics and proteomics approach revealed sexually dimorphic molecular signatures in primary mouse hepatocyte
Sexual dimorphism plays a critical role in disease pathophysiology, but the subtlety and complexity of these differences, along with a lack of precise comparative methods, hinder the advancement of precision medicine and drug development. This limitation is particularly evident in metabolic dysfunction–associated steatotic liver disease (MASLD), where sex-specific molecular mechanisms remain insufficiently understood. To address this gap, we employed an advanced integrative N-glycoproteomics and proteomics approach to systematically analyze sex-biased molecular signatures in primary mouse hepatocytes (PMHs) under healthy and MASLD conditions. Our analysis identified 280 sex-biased proteins and 39 sex-biased N-glycosites, and KEGG enrichment revealed that female-biased molecules were primarily involved in lipid metabolism, while male-biased molecules were associated with inflammation and cytoskeletal remodeling. A combined dataset of 302 sex-biased molecules was further analyzed using protein–protein interaction (PPI) analysis and Rc value calculations, resulting in the identification of 21 hub proteins and 2 hub N-glycosites as MASLD-associated sex-biased signatures. Notably, MASLD amplified proteomic sex differences while attenuating them in N-glycosylation. Western blot validation of key signatures, including female-biased MVK and male-biased LGALS3, highlighted distinct molecular adaptations between the sexes in MASLD progression. Our study introduced an advanced analytical framework for high-resolution comparative molecular profiling by integrating N-glycoproteomics with proteomics, providing valuable insights into sex-biased molecular signatures, enhancing preclinical model development, and advancing sex-specific therapeutic strategies in MASLD research and broader biological systems. Graphical Abstract
- Open Access
- 19 March 2025
- Published by Elsevier in Journal of Pharmaceutical Analysis
- Vol. 15 (11)
Signatures of proteomics and glycoproteomics revealed liraglutide ameliorates MASLD by regulating specific metabolic homeostasis in mice
- 19 March 2025
- Published by Elsevier in Journal of Pharmaceutical Analysis
- Vol. 15 (11)
Open AccessSignatures of proteomics and glycoproteomics revealed liraglutide ameliorates MASLD by regulating specific metabolic homeostasis in mice
- Open Access
- 9 February 2025
- Published by MDPI AG in Laboratories
- Vol. 2 (1) , 5
Enhancing Chemical Laboratory Safety with Hazards Risks Mitigation and Strategic Actions
Chemical laboratories, as the cornerstone of scientific innovation, face inherent risks due to the nature of their operations. Hazards such as flammable, explosive, and corrosive chemicals, combined with high-pressure and high-temperature conditions, present significant safety challenges. Accidents not only jeopardize the health and safety of personnel but also risk equipment damage, environmental pollution, and broader societal impacts. Ensuring a safe laboratory environment demands a multifaceted approach involving all stakeholders. Institutional managers must establish and enforce comprehensive safety management systems, covering chemical storage, equipment handling, and waste disposal. Laboratory directors play a pivotal role in overseeing the implementation of these protocols, ensuring all members are well-trained and compliant. Laboratory personnel, as direct operators, must adhere to safety procedures, utilize protective equipment, and responsibly manage experimental waste. By fostering a culture of safety and collaboration, laboratories can effectively mitigate risks, safeguard research environments, and advance scientific progress without compromising well-being.
- 9 February 2025
- Published by MDPI AG in Laboratories
- Vol. 2 (1) , 5
Open AccessEnhancing Chemical Laboratory Safety with Hazards Risks Mitigation and Strategic Actions
Chemical laboratories, as the cornerstone of scientific innovation, face inherent risks due to the nature of their operations. Hazards such as flammable, explosive, and corrosive chemicals, combined with high-pressure and high-temperature conditions, present significant safety challenges. Accidents not only jeopardize the health and safety of personnel but also risk equipment damage, environmental pollution, and broader societal impacts. Ensuring a safe laboratory environment demands a multifaceted approach involving all stakeholders. Institutional managers must establish and enforce comprehensive safety management systems, covering chemical storage, equipment handling, and waste disposal. Laboratory directors play a pivotal role in overseeing the implementation of these protocols, ensuring all members are well-trained and compliant. Laboratory personnel, as direct operators, must adhere to safety procedures, utilize protective equipment, and responsibly manage experimental waste. By fostering a culture of safety and collaboration, laboratories can effectively mitigate risks, safeguard research environments, and advance scientific progress without compromising well-being.